__NUXT_JSONP__("/drugs/Rivoceranib_Mesylate", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1218779-75-9",chebiId:b,chemicalFormula:b,definition:"The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.",fdaUniiCode:"TK02X14ASJ",identifier:"C74012",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C1742","C1967"],synonyms:["Apatinib Mesylate","RIVOCERANIB MESYLATE",c,"YN-968D1","YN968D1"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRivoceranib_Mesylate",extension:".json",createdAt:"2021-10-30T13:44:15.473Z",updatedAt:"2021-10-30T13:44:15.483Z"}}],fetch:{},mutations:void 0}}("Rivoceranib_Mesylate","","Rivoceranib Mesylate")));